Organicell Regenerative Medicine, Inc.
OTC:OCEL
0.0069 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4.558 | 6.491 | 5.597 | 3.056 | 1.702 | 0.965 | 0.57 | 0.185 | 0.148 | 0.049 | 0.083 | 0.087 | 0.018 |
| Cost of Revenue
| 0.508 | 0.754 | 0.548 | 0.399 | 0.301 | 0.209 | 0.161 | 0.094 | 0.049 | 0.02 | 0.044 | 0.061 | 0.011 |
| Gross Profit
| 4.051 | 5.737 | 5.05 | 2.657 | 1.401 | 0.755 | 0.409 | 0.09 | 0.098 | 0.029 | 0.039 | 0.026 | 0.007 |
| Gross Profit Ratio
| 0.889 | 0.884 | 0.902 | 0.87 | 0.823 | 0.783 | 0.718 | 0.489 | 0.665 | 0.592 | 0.464 | 0.299 | 0.392 |
| Reseach & Development Expenses
| 0.923 | 0.791 | 1.12 | 0.234 | 0.055 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 10.818 | 14.58 | 17.794 | 15.095 | 3.178 | 4.245 | 9.051 | 1.134 | 0.861 | 0.095 | 0.071 | 0.038 | 0.019 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.818 | 14.58 | 17.794 | 15.095 | 3.178 | 4.245 | 9.051 | 1.134 | 0.861 | 0.095 | 0.071 | 0.038 | 0.019 |
| Other Expenses
| -0.029 | 0.345 | 0.025 | 0.033 | 0.085 | 0.021 | 0.009 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 10.818 | 14.58 | 17.794 | 15.095 | 3.178 | 4.245 | 9.051 | 1.134 | 0.861 | 0.095 | 0.071 | 0.038 | 0.019 |
| Operating Income
| -6.767 | -8.843 | -12.744 | -12.438 | -1.776 | -3.49 | -8.642 | -1.043 | -0.763 | -0.066 | -0.032 | -0.012 | -0.012 |
| Operating Income Ratio
| -1.485 | -1.362 | -2.277 | -4.07 | -1.044 | -3.618 | -15.165 | -5.643 | -5.168 | -1.338 | -0.388 | -0.142 | -0.649 |
| Total Other Income Expenses Net
| 0.212 | -0.054 | -0.012 | -0.145 | 0.038 | 0.287 | 0.105 | -0.013 | 0.787 | 0 | 0 | 0 | 0 |
| Income Before Tax
| -6.987 | -8.897 | -12.757 | -12.583 | -1.738 | -3.431 | -9.113 | -1.056 | -0.763 | -0.066 | -0.032 | -0.012 | -0.012 |
| Income Before Tax Ratio
| -1.533 | -1.371 | -2.279 | -4.118 | -1.021 | -3.558 | -15.991 | -5.712 | -5.168 | -1.338 | -0.388 | -0.142 | -0.649 |
| Income Tax Expense
| 0.403 | 0.054 | 0.063 | 0.21 | 0.13 | -0.235 | -0.236 | 0.197 | -0.025 | 0 | 0 | 0 | 0 |
| Net Income
| -6.987 | -8.95 | -12.82 | -12.793 | -1.869 | -3.462 | -8.972 | -1.253 | -0.738 | -0.066 | -0.032 | -0.012 | -0.012 |
| Net Income Ratio
| -1.533 | -1.379 | -2.29 | -4.187 | -1.098 | -3.589 | -15.745 | -6.778 | -5.001 | -1.338 | -0.388 | -0.142 | -0.649 |
| EPS
| -0.99 | -1.57 | -2.42 | -3.81 | -0.8 | -2.55 | -16 | -2 | -2 | -2 | -0.044 | 0 | -0.11 |
| EPS Diluted
| -0.99 | -1.57 | -2.42 | -3.81 | -0.8 | -2.55 | -16 | -2 | -2 | -2 | -0.044 | 0 | -0.11 |
| EBITDA
| -6.31 | -8.166 | -12.666 | -12.368 | -1.677 | -3.461 | -8.613 | -1.043 | -0.763 | -0.066 | -0.032 | -0.012 | -0.012 |
| EBITDA Ratio
| -1.384 | -1.258 | -2.263 | -4.048 | -0.985 | -3.588 | -15.115 | -5.641 | -5.167 | -1.338 | -0.388 | -0.142 | -0.649 |